Episode Player

Send us Fan Mail

A lung scan can do more than show a shadow on an image. We sit down with Dr Andreas Fouras, MD, CEO and founder of 4DMedical, to talk about the shift from “how the lung looks” to “how the lung works” and why functional lung imaging is becoming a commercial reality across Australia, Europe and the United States.

We dig into the binding agreement to acquire Austria’s contextflow and why an established Vienna-based team with existing insurance reimbursement contracts in Germany can beat a slow greenfield build. Andreas explains the uncomfortable truth in medtech: FDA clearance and CE marking open doors, but reimbursement is what builds a durable business. We also explore how adding AI lung cancer screening and workflow tools complements CT:VQ™  and CT:VQ™ , creating a fuller clinical pathway from screening through to functional assessment and procedure planning.

Closer to home, we cover the TGA approval and ARTG inclusion for CT:VQ™   and why Australia’s high CT scanner density makes a software-only, non-contrast solution so compelling. From there we head to the US, looking at adoption at leading sites and the commercial meaning of the SimonMed Imaging agreement across 170 outpatient centres, including the value of health economics data for payer conversations. If you want a clear view of what to watch through 2026, we outline the practical metrics that matter: site wins, network progress and the scan volumes that drive SaaS revenue. Subscribe, share the episode with a mate, and leave a review to help more listeners find ASX Briefs.